International and national guidelines on the treatment of chronic nonhypovolaemic hypotonic hyponatraemia differ; therefore, we have undertaken this systematic review and metaanalysis to investigate the efficacy and safety of interventions for the treatment of chronic nonhypovolaemic hypotonic hyponatraemia. Following registration of the review protocol with PROSPERO, systematic literature searches were conducted to identify randomized and quasi-randomized controlled trials assessing any degree of fluid restriction or any drug treatment with the aim of increasing serum sodium concentration in patients with chronic nonhypovolaemic hypotonic hyponatraemia. Where appropriate, outcome data were synthesized in a meta-analysis. A total of 45 716 bibliographic records were identified from the searches and 18 trials (assessing conivaptan, lixivaptan, tolvaptan and satavaptan) met the eligibility criteria. Results suggest that all four vasopressin receptor agonists ("vaptans") significantly improve serum sodium concentration. Lixivaptan, satavaptan and tolvaptan were associated with greater rates of response versus placebo. There was no evidence of a difference between each of the vaptans compared with placebo for mortality, discontinuation and rates of hypernatraemia. No RCT evidence of treatments other than the vaptans for hyponatraemia such as oral urea, salt tablets, mannitol, loop diuretics demeclocycline or lithium was identified. Vaptans demonstrated superiority over placebo for outcomes relating to serum sodium correction. Few trials documented the potential benefit of vaptans on change in health-related quality of life as a result of treatment. There was also a lack of high-quality RCT evidence on the comparative efficacy of the vaptans and other treatment strategies for the treatment of chronic nonhypovolaemic hypotonic hyponatraemia.
Introduction
Hyponatraemia (HN) serum sodium concentration <135 mmol/l is the most common disorder of body fluid and electrolyte imbalance. [1] [2] [3] It is associated with various clinical conditions [1] [2] [3] and reportedly occurs in 15-30% of hospital admissions. 2, 3 Hyponatraemia may be associated with iatrogenic causes or, in approximately 35% of cases, 4 be caused by the kidneys retaining water because of excess vasopressin secretion. 5 The most common noniatrogenic cause of nonhypovolaemic hypotonic hyponatraemia is the syndrome of inappropriate antidiuretic hormone secretion (SIADH), a disorder of impaired water excretion due to the inability to suppress the secretion of vasopressin resulting in reduced urinary volumes. If water intake exceeds the reduced urine output, the resulting water retention leads to the development of hyponatraemia. 3, 5 Other causes include excessive fluid intake, excessive solute losses, renal failure, hormonal abnormalities and low solute intake. 3 Nonhypovolaemic hyponatraemia is not a single diagnosis but a combination of a very heterogeneous group of clinical circumstances with variable clinical outcome depending on the hyponatraemia aetiology. Current treatment of nonhypovolaemic hyponatraemia depends primarily on ascertaining the underlying cause and must be undertaken carefully to avoid too rapid an increase in serum sodium concentration. Overly rapid correction can result in osmotic demyelination syndrome. 3, 6 Fluid restriction is generally the first-line treatment for chronic hyponatraemia in the absence of relevant symptoms, including HN secondary to SIADH. Hypertonic saline should be administered in acute HN and in chronic HN in the presence of severe or moderate symptoms. However, there is no consensus regarding the optimal second-line options when fluid restriction is not appropriate or does not adequately correct the hyponatraemia. 1, 3, 5 Alternative treatment strategies include oral urea, salt tablets, mannitol, loop diuretics demeclocycline, lithium and recently vasopressin receptor antagonists (vaptans). 1, 3, 5 Vaptans block the V2 receptors in the kidney facilitating aquaresis and restoring serum sodium level through restoration of normal circulating volume. 3, 6 Advice in national and international guidelines on recommended treatments varies. A number of national guidelines recommend tolvaptan as a second-line option for treating hyponatraemia secondary to SIADH when fluid restriction is unsuitable, 3, 7, 8 but European guidelines in endocrinology, nephrology and intensive care medicine do not recommend the use of vaptans for this indication. 1, 9, 10 Given this difference in published guidelines, this systematic review was undertaken to identify the randomized and quasirandomized controlled trial evidence for the effectiveness of interventions to treat chronic nonhypovolaemic hypotonic hyponatraemia by assessing outcomes relating to change in serum sodium concentration, all-cause mortality, health-related quality of life outcomes, outcomes potentially related to overcorrection of serum sodium concentration, treatment-specific side effects and treatment discontinuation.
Methods
A systematic review was undertaken according to the principles of systematic reviewing in the Cochrane handbook. 11 Two independent clinical experts (not involved in the conduct of the systematic review) peer-reviewed the protocol, statistical plan and draft report. The protocol was registered on PROSPERO 12 (CRD42015016670). Studies were eligible for inclusion if they assessed the treatment of patients over 14 years of age. Children (aged 28 days to 14 years) were ineligible because they have significantly different physiological requirements and clinical circumstances to adults. Chronic nonhypovolaemic hypotonic hyponatraemia was defined as the presence of three criteria:
• Hyponatraemia >48 h; • Serum osmolality <280 mOsm/kg; • Serum sodium concentration <135 mmol/l.
Populations in the identified studies were not always clearly defined, particularly in relation to the duration of chronic hyponatraemia. For this reason, the inclusion criteria were broadened to include studies where hyponatraemia of more than 48 h had not been explicitly reported, but in which chronic hyponatraemia was a known feature of the chronic disease states being assessed (e.g. SIADH or chronic uncontrolled heart failure) on the assumption of a chronic process. A protocol amendment was recorded.
Randomized or quasi-randomized (i.e. trials in which the methods of allocating people to a treatment arm were not random, but were intended to produce similar groups 11 ) controlled trials published as full reports were eligible for review. Eligible trials compared any degree of fluid restriction or any drug treatments with the aim of increasing serum sodium concentration in patients with chronic nonhypovolaemic hypotonic hyponatraemia. Outcomes of interest to the review included: all-cause mortality, health-related quality of life outcomes, length of hospital stay, response (an increase in serum sodium of ≥5 mmol/l or normalization of serum sodium concentration (≥135-145 mmol/l)), serum sodium concentration (mmol/l) at end of treatment or change from beginning to end of treatment, outcomes potentially related to over-correction of serum sodium concentration or rapid increase in serum sodium (i.e. more than 12 mmol/l in 24 h or more than 18 mmol/l in 48 h), any treatment-specific side effects and treatment discontinuation. Searches were conducted in MEDLINE, EMBASE, PubMed, Cochrane Library, Science Citation Index, World Health Organisation International Clinical Trials Registry Platform and clinicaltrials.gov. Selected conference proceedings were searched. The detailed search strategies are provided in the Appendix S1-S3.
Two independent reviewers screened the search results against the eligibility criteria in the protocol. Any disagreements were discussed with a third reviewer. Studies excluded following fulltext review are listed in the Appendix S1-S3.
Two independent reviewers conducted data extraction and quality assessment. Details of the funding source, trial design and methodology, patient characteristics, treatment and permitted dose adjustments, statistical methods used and prespecified outcomes (including the unit of measurement, analysis population and effect size) were extracted. The Cochrane Assessment of Risk of Bias tool 11 was used to assess risk of bias at the study level. High risk of bias was assumed if at least one quality criterion was not adequately met.
The results of similar studies were statistically pooled using both fixed-effects and random-effects models. RevMan (version 5Á3) was used to calculate pairwise meta-analysis using standard frequentist approaches. 11 Studies were drawn from the published literature; therefore, the effects being estimated in each study are likely to vary. There is also a degree of heterogeneity among studies in how outcomes are measured and in the ways that missing data were handled. Consequently, we report the most appropriate meta-analysis model: the random-effects model. Risk ratio (RR) has been used as a summary statistic (with 95% confidence intervals (CI)). RR has been shown to be more understandable and easier to interpret.
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Statistical heterogeneity was assessed for each pairwise comparison informed by at least two trials. Forest plots assess heterogeneity and present the I-squared statistic, between-study variance (tau-squared) and the P-value of the heterogeneity statistic Q. I-squared values of 25%, 50% and 75% were defined as representing low, moderate and high heterogeneity.
Following data extraction, an assessment of the studies identified, and after consultation with independent clinical experts, it was agreed that in studies with more than one treatment group receiving different doses of the same drug, the treatment groups were collapsed into one single pairwise comparison versus placebo.
It was also agreed that it was appropriate to combine data at any time point after 4 days of treatment initiation, on the understanding that the treatment effect of vaptans plateaus at 4 days and any additional treatment is effectively maintaining this effect. For the change from baseline outcomes and for incidence of response, some trials reported data at a number of time points and the data were not always consistent over time. Where this was the case, data for all time points are reported and the trials are grouped by similar time point for the meta-analyses. A post hoc 'end-point' analysis, (i.e. meta-analysis including the end of study data for each trial) was also conducted for these outcomes.
We planned to analyse publication bias using funnel plots.
Subgroup analyses were prespecified in relation to the underlying condition associated with hyponatraemia. Sensitivity analyses were explored for each meta-analysis excluding the following trials in turn:
• Average serum sodium concentration at baseline >130 mmol/l;
• >50 patients per treatment arm to explore how larger trials influence the results;
• Imposed mandatory fluid restriction;
• High risk of bias;
• Non-English language studies;
• Unpublished studies;
• Industry funding;
• Based on country;
• Based on diagnostic criteria.
The primary meta-analyses for each comparison include all eligible trials that reported data for that outcome, regardless of underlying condition. Results of the SIADH and cancer subgroups are also reported here, where data were available.
Results
The searches retrieved 45 716 records. Following study selection ( Fig. 1) , 18 trials met the eligibility criteria or reported data for an eligible subgroup. Two trials assessed conivaptan, 13, 14 four assessed lixivaptan, [15] [16] [17] [18] three assessed satavaptan [19] [20] [21] and nine assessed tolvaptan. [22] [23] [24] [25] [26] [27] [28] [29] There were no RCTs published assessing other known interventions such as urea, sodium tablets or mannitol. We contacted the authors of ten studies and Otsuka, to seek additional information about the trials' design and outcomes. Otsuka (manufacturer of tolvaptan and funder of this review) provided information for six trials of tolvaptan vs placebo and the authors of two further trials responded. 14, 20 A summary of the characteristics of the included trials is presented in Table 1 . All 18 trials were randomized multicentre trials. Seventeen were double-blind trials and reported to be placebocontrolled. One trial was open label describing fluid restriction as an active control. 23 In two trials, the double-blind period was followed by a 1-year open-label noncomparative extension with flexible dosing: for this review, only results reported throughout the double-blind period were extracted. 19, 21 All trials were supported or funded by pharmaceutical companies. The underlying cause of hyponatraemia varied across the trials. Some trials reported data for a specific population and others included patients with various underlying causes. Three trials assessed hyponatraemia in patients with SIADH, 15, 21, 22 four assessed hyponatraemia in patients with congestive heart failure, [24] [25] [26] [27] two assessed hyponatraemia in patients with cirrhosis, 17, 20 and one assessed hyponatraemia in patients with cancer. 28 The other eight trials assessed hyponatraemia in patients with a range of underlying conditions. In these trials, results were reported for subgroups of patients in the Study of Ascending Levels of Tolvaptan in hyponatraemia (SALT 1 and SALT 2) trials with SIADH, 30 cirrhosis, 31 SIADH and cancer, 32 and schizophrenia 33 ; one trial reported some results for a subgroup of patients with cirrhosis and SIADH 18 and one trial reported some results for a subgroup of patients with congestive heart failure (CHF).
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All trials reported assessing patients with nonhypovolaemic hyponatraemia, but only five trials specifically reported patients' fluid status. In two trials, 15, 16 all patients were categorized as euvolaemic. In the other three trials, 50-70% of patients in each treatment arm were euvolaemic and the remainder were hypervolaemic. 13, 14, 29 Sixteen trials reported primary outcomes related to serum sodium correction, serum sodium normalization or change from baseline. Two trials reported weight change 24, 27 and worsening heart failure 27 as primary outcomes and reported results for the hyponatraemia subgroup in a larger CHF population. 27 The majority of trials used the last observation carried forward (LOCF) method to impute missing data. LOCF can lead to bias and is only appropriate in cases where a relatively recent observation has been carried forward. 11 The majority of trials did not report this and therefore studies using this method of imputation were categorized as having an unclear risk of bias. Two trials had low risk of bias, 14, 20 five had high risk of bias 21,23,27,28 and 11 did not report adequate detail and were categorized as unclear risk of bias indicating that there is a substantial risk of bias across the data set as a whole. There were no significant differences between the fixed-and random-effects results for any outcome assessed.
Results are shown in Tables 2 and 3 . The I 2 statistic presented in the tables indicates the level of statistical heterogeneity for each meta-analysis. All of the comparisons had low to moderate levels of heterogeneity unless otherwise stated.
Response was defined in the protocol as an increase in serum sodium of ≥5 mmol/l and/or normalization of serum sodium concentration (≥135-145 mmol/l). A random-effects meta-analysis suggests that patients randomized to lixivaptan, [15] [16] [17] For the change in the daily area under the curve (AUC) of serum sodium, in the random-effects meta-analyses, patients randomized to lixivaptan at day 3 15, 16 and tolvaptan at day versus placebo all reported significantly greater changes in patients randomized to vaptans. Trials assessing tolvaptan at days 10-14 had high levels of heterogeneity (I 2 = 75%).
There was no significant difference between patients receiving any of the vaptans compared to placebo in single trials or pooled analyses for mortality, treatment discontinuation and incidence of hypernatraemia.
Four trials comparing tolvaptan and placebo documented the incidence of osmotic demyelination syndrome. 23, 25, 29 No incidents were reported in either treatment arm by these trials. A rapid increase in serum sodium was defined as an increase of more than 12 mmol/l in 24 h or more than 18 mmol/l in 48 h. Pooled analyses of two trials of conivaptan 13, 14 and three trials of satavaptan [19] [20] [21] found no differences in the incidence of a rapid increase in serum sodium in patients randomized to either intervention or placebo. While there were no differences individually in the three tolvaptan trials, 23, 29 when pooled, the incidence of a rapid rise in serum sodium levels was significantly greater in patients randomized to tolvaptan than placebo (RR 9Á85 [95% CI: 1Á27, 76Á35] P = 0Á03). However, because of the low number of events in the treatment arm (5 and 4 events in SALT 1 and SALT 2, respectively) and no events in the placebo arm of each trial, the size of the treatment effect is uncertain. Gheorghaide (2006) reported zero events in both treatment arms and did not contribute to the meta-analysis. 23 Few trials reported health-related quality of life and, those that did, used various generic instruments none of which are specifically designed to assess hyponatraemia (see Appendix S1-S3). One trial of lixivaptan 15 reported change from baseline in the Medical Outcomes Survey 6-item cognitive function scale; higher scores indicated less impairment of cognitive functioning. The trial was carried out in patients with SIADH. Data were reported at weeks 8 and 12. At both time points, significantly greater increases from baseline were observed in the lixivaptan group compared with placebo. The two SALT trials reported change from baseline in the Short Form-12 mental health composite score (SF-12 MCS). 18, 19, 34, 35 At day 30 in SALT 1 and in the SIADH subgroup of the two SALT trials, patients receiving tolvaptan had a significantly greater increase in SF-12 MCS score compared with patients receiving placebo. There was also a significant difference in favour of tolvaptan when data were pooled for the two SALT trials at day 30 mean difference: 4Á76 (95% CI: 0Á11 to 9Á41).
With the exception of a greater incidence of serious adverse events in patients receiving tolvaptan in the EVEREST trial, which assessed the safety of tolvaptan 30 mg at 60 days in patients with heart failure, there was no evidence of a difference between any of the other treatments identified compared with placebo for the incidence of adverse and serious adverse events and withdrawal due to adverse events. Adverse event data could not be pooled because of differences in the underlying condition of patients across trials and the differences in the time point assessed.
Comparative length of hospital stay could not be assessed because of the different settings reported for the studies (some studies required patients to be hospitalized for some or all of the trial period, whereas others did not) and the variation in underlying conditions. None of the sensitivity analyses significantly altered the metaanalyses results. Sensitivity analyses excluding unpublished studies were not undertaken because all of the included studies were identified in the published literature. Sensitivity analyses excluding studies using the following filters were not explored: diagnostic criteria (too much variation across trials and differences in underlying conditions), source of funding (all studies were industry funded), country (insufficient variation to warrant investigation).
We planned to analyse publication bias, but none of the analyses had a sufficient number of studies to conduct funnel plot analysis. 11 
Discussion
This systematic review and meta-analysis identified RCT evidence only for vaptans in the treatment of chronic nonhypovolaemic hypotonic hyponatraemia. No RCTs or quasi-RCT evidence was identified for any alternative interventional strategy. Vaptans are more effective than placebo for the treatment of hyponatraemia for outcomes related to serum sodium correction.
There was limited evidence on the impact of vaptans treating hyponatraemia on other relevant outcomes, such as quality of life. Patient-reported outcome measures were inconsistently and infrequently assessed across trials and, therefore, conclusions cannot be drawn regarding patients' experiences of the different vaptans. The results of the meta-analyses for each treatment at various time points for response, mortality discontinuation, incidence of hypernatraemia and incidence of rapid increase in serum sodium. Results are presented as relative risk with 95% confidence intervals. Cells highlighted in grey are those in which there is a statistically significant difference in favour of the active treatment compared with placebo.
CI, confidence interval; RR, risk ratio; SIADH, syndrome of inappropriate antidiuretic hormone; SG, subgroup.
© There was no evidence of a difference between placebo and any of the vaptans on mortality as an outcome but this was not a primary outcome in the studies examined. A recent review and meta-analysis 36 found that improvements in serum sodium, in hyponatraemic patients with a range of clinical conditions, are associated with a reduction in overall mortality. However, similar to other studies this observation does not establish a cause-effect relationship but is hypothesis-generating. The lack of correction might contribute directly to poor outcomes or might be a biomarker for the severity of the underlying comorbidities.
There is currently controversy regarding the optimal treatment of hyponatraemia related to SIADH and the guidelines available recommend a number of strategies to treat hyponatraemia. 1, 3, 8 The guidance is clear that in the acute setting hyponatraemia can be corrected relatively quickly without longer-term adverse consequences. However, it is less clear in the chronic setting (the presence of hyponatraemia >48 h). Similarly, severe hyponatraemia in which neurological symptoms are apparent requires intervention and most clinicians agree that hypertonic saline to elevate the serum sodium to a safe level of greater than 120 mmol/l is appropriate; however, in mild to moderate hyponatraemia as in the current analysis, optimal treatment strategies are less clear.
The main goal of therapy for moderate to severe hyponatraemia is to reliably increase the serum sodium concentration and safely minimize the risk of the brain swelling and also to improve hyponatraemic symptoms, while avoiding the devastating potential neurological sequelae caused by too rapid or too great a correction of the sodium concentration. To date, no therapy fulfilled these criteria; 3% saline improves serum sodium, but nearly 10% of patients will experience excessive correction, as a result of water diuresis that occurs during therapy. Some have advocated concomitant use of desmopressin to avoid this potential complication, but evidence from RCTs is lacking. Assessment of other parameters of patient-related outcomes is lacking and requires further study.
Thus, despite the observation in clinical care that hyponatraemia is the commonest occurring electrolyte disturbance, it is striking that the only intervention for which there are any data from RCTs are the vaptans. There are no data from RCTs on the efficacy and safety of other commonly used interventions such as oral urea tablets, salt tablets, hypertonic saline loop diuretics, mannitol, demeclocycline or lithium.
Implications for practice and further research recommendations
RCT evidence of the effectiveness of interventions to treat hyponatraemia was identified for conivaptan, lixivaptan, tolvaptan and satavaptan. Our analysis suggests that the efficacy profile across the vaptans is similar. Currently, tolvaptan has EU approval for the treatment of hyponatraemia secondary to SIADH and US approval for clinically significant nonhypovolaemic hyponatraemia (serum sodium <125 mEq/L or less). Satavaptan was withdrawn from the European Medicines Agency in 2008, 37 lixivaptan is not licensed, and conivaptan (IV) is approved for the treatment of euvolaemic hyponatraemia in hospitalized patients only in the United States. Clinically the question remains regarding the relevance of the evolution and aetiology of hyponatraemia in different conditions; that is, is the hyponatraemia a "primary" feature in euvolaemic disorders which are often due to SIADH, or is it a "secondary" and variable feature, as seen in patients with heart failure, nephrotic syndrome and/or liver disease where there is often hypervolaemia. This is a complex concept but where the hyponatraemia is predominantly a secondary feature, the outcomes should be assessed as those of the underlying disease processes. Thus, management of the heart failure for example should lead to improved sodium levels. In the case where the intervention is for a "primary" feature such as in SIADH which responds to specific treatment to improve serum sodium such as fluid restriction or vaptans, the rate of change in serum sodium can be used as a surrogate biomarker of outcome of this therapy, particularly if there are no suggestions of adverse outcomes. It, however, is not a marker of overall outcome from the underlying disorder such as neoplasm or pneumonia which will be dictated by specific more prolonged therapy if feasible.
Thus, for future studies treating hyponatraemia we recommend standard measurement criteria of clinical status at inclusion. These measures should include the clinical hydration state, co-prescribed medications, nadir sodium levels and presence/absence of cognitive or other symptoms/signs associated with hyponatraemia. They should also include the underlying pathology for "secondary" hyponatraemia where known, and the pretreatment plasma/urine osmolalities and electrolytes that should be common to all studies. Further, a standard set of outcome measures should be agreed in relation to the sodium change and primary disease state. Such criteria are necessary to co-ordinate clinical research to facilitate a future clinical consensus in this complex but relatively common area of clinical practice, which is made more challenging because it intersects multiple medical and surgical specialties as well as primary care.
Recent clinical guidelines suggest that individualized care is optimal for treating patients. Tolerability is also a key component to effective therapy. There were little data available to determine which specific subgroups of patients might benefit from treatment with a vaptan and no data available on which patients would benefit from other interventions suggested in clinical guidelines.
All of the studies identified in this review were placebo-controlled trials. In the absence of direct evidence of the relative efficacy of vaptans for chronic nonhypovolaemic hypotonic hyponatraemia, there is potential for indirect treatment comparisons. Well-conducted RCTs comparing relevant comparators in use in current practice, such as vaptans, fluid restriction, urea, sodium tablets or hypertonic saline solution are required, to gain more evidence on the comparative effectiveness of different treatments and to explore which subgroups might benefit most from individual treatments. This will allow further revision of clinical guidelines. This review was informed by extensive searches to ensure that as many relevant studies as possible were identified. None of the comparisons in these analyses had sufficient studies to assess publication bias reliably using funnel plots.
This review has benefited from the provision of additional data for six trials of tolvaptan, [34] [35] [36] [37] [38] [39] one of conivaptan 14 and one of satavaptan. 20 Authors of the other studies did not provide similar data: we do not know how that missing data might impact on the risk of bias assessment or results. This review considered all doses of each vaptan together and collapsed doses into a single treatment arm. This approach assumes that all doses of a drug have a similar treatment effect, which may not always be the case. The majority of trials adopted an approach allowing titration and dose adjustments at set points in the trial which may be more reflective of clinical practice. While there were some differences in the permitted dose adjustments and fluid restriction across trials, these differences were considered unlikely to impact on the overall treatment effect. Trials with mandatory fluid restriction were excluded from the meta-analyses in a sensitivity analysis and this had little impact on the treatment effect.
Flaws in the design, conduct and analysis of RCTs can lead to bias and raise questions about the validity of their findings. The trials in this review varied in design and quality; however, a sensitivity analysis excluding high risk of bias studies did not have a great impact on the direction or significance of the results. This review did not consider other types of evidence such as case series and case reports which may provide additional information, particularly in relation to safety and the lesser reported adverse events which may be under-estimated in published RCTs.
The trials varied in terms of the underlying causes of hyponatraemia. Some studies assessed a mixed population (i.e. any underlying cause), while others assessed hyponatraemia in specific populations of patients with heart failure, cirrhosis or SIADH. Where possible, subgroup analyses were also carried out by underlying condition.
Conclusions regarding the safety of each treatment should be drawn with care and should take into consideration the varying assessment time points and different underlying conditions.
Conclusions
Vaptans are an evidence-based treatment to increase serum sodium in patients with nonhypovolaemic hyponatraemia. The RCT evidence indicates that each of the vaptans significantly improves serum sodium concentration compared with placebo and is associated with greater rates of response than placebo. There was no evidence of a difference between any of the vaptans compared with placebo for mortality, discontinuation and rates of hypernatraemia; however, higher rates of a rapid increase in serum sodium were observed in the tolvaptan-treated patients in the pooled analysis. RCTs are required to determine the comparative efficacy of vaptans, fluid restriction and the other treatments currently used in clinical practice or recommended in guidelines for chronic hypotonic nonhypovolaemic hyponatraemia.
